Vincristine sulfate

Catalog No.S1241 Synonyms: Leurocristine

Vincristine sulfate Chemical Structure

Molecular Weight(MW): 923.04

Vincristine sulfate is an inhibitor of polymerization of microtubules by binding to tubulin with IC50 of 32 μM in a cell-free assay.

Size Price Stock Quantity  
USD 70 In stock
USD 270 In stock
USD 870 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 21 Publications

Purity & Quality Control

Choose Selective Microtubule Associated Inhibitors

Biological Activity

Description Vincristine sulfate is an inhibitor of polymerization of microtubules by binding to tubulin with IC50 of 32 μM in a cell-free assay.
Targets
Microtubules [1]
(Cell-free assay)
32 μM
In vitro

Vincristine inhibits net addition of tubulin dimers at assembly ends of steady-state microtubules with Ki of 85 nM. [1] At low concentrations, Vincristine stabilizes the spindle apparatus resulting in failure of the chromosomes to segregate leading to metaphase arrest and inhibition of mitosis. At higher concentrations, Vincristine may disrupt and induce total depolymerization of microtubules. [2] Vincristine induces apoptosis in tumor cells and inhibits SH-SY5Y cell proliferation with IC50 of 0.1 μM. Vincristine induces mitotic arrest and promots the expression of caspase-3 and -9 and cyclin B, while decreasing the expression of cyclin D. [4] Vincristine induced neurotoxicity is caused by interference with microtubule function, which results in blockage of axonal transport and thus in axonal degeneration. [5]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HepG2.2.15 M1;qc2NmdGxiVnnhZoltcXS7IFHzd4F6 MY[wMVAvPSEQvF2= MVyyOEBp NHXNPVdl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImg[I9{\SCmZYDlcoRmdnSueR?= Mo\WNlU3PjN5Nkm=
HepG2-HBV1.1 NF36NZlCeG:ydH;zbZMhSXO|YYm= NGHlN5oxNTBwNTFOwG0> MYmyOEBp MWLpcoR2[2W|IHHwc5B1d3OrczDkc5NmKGSncHXu[IVvfGy7 MlzKNlU3PjN5Nkm=
HepG2.2.15 NInHXWxHfW6ldHnvckBCe3OjeR?= M2KwOFAvOSEQvF2= NWLaUG94OjRiaB?= NXraZ4g3eHKxbX;0[ZMhcGWyYYTpeIl{KEJidnnyeZMheHKxdHXpckBmgHC{ZYPzbY9v NF30blYzPTZ4M{e2PS=>
HepG2-HBV1.1 NGrnPZJHfW6ldHnvckBCe3OjeR?= MVWwMlEh|ryP NVrmeHZUOjRiaB?= NYP6emRYeHKxbX;0[ZMhcGWyYYTpeIl{KEJidnnyeZMheHKxdHXpckBmgHC{ZYPzbY9v MUKyOVY3Ozd4OR?=
HepG2-HBV1.1 NVnCXJFtTnWwY4Tpc44hSXO|YYm= NWjuN49vOC5zIN88US=> MWi0PEBp Mn[4dJJwdW:2ZYOgZ4VtdCCneHPy[ZRqd25ib3[gbIVx[XSrdHnzJGIhfmm{dYOgcpVkdGWxY3Hwd4lleyCrboP0[YFlKG:oIHjldIF1cXSrczDCJJZqenW|IFThcoUheGG{dHnjcIV{ NHrQZ5YzPTZ4M{e2PS=>
HepG2-HBV1.1 NXrm[|N6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mof2NE4yKM7:TR?= NHTpU|kyNTViZB?= MWDpcohq[mm2czD0bIUheHKxbHnm[ZJifGmxbjD0bY1mKGSncHXu[IVvfGy7 M3fYZlI2PjZ|N{[5
HepG2-HBV1.1 MlrtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYCwMlEh|ryP MWixMVUh\A>? Mnv4bY5pcWKrdIOgeIhmKHC{b3zp[oVz[XSrb36geIlu\SCmZYDlcoRmdnSueR?= MlW0NlU3PjN5Nkm=
HepG2-HBV1.1 NVzVflV6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Moi4NE4yKM7:TR?= MWCxNk04OiCq MoPUbY5lfWOnczDj[YxtKGO7Y3zlJIFzemW|dDDheEBUNXCqYYPl M371PFI2PjZ|N{[5
HepG2-HBV1.1 NX3Gcmh2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4q1W|AvOSEQvF2= MWKxNk04OiCq NEXuVIVqdmS3Y3XzJINmdGxiY4njcIUh[XK{ZYP0JIF1KFNvcHjhd4U> MYWyOVY3Ozd4OR?=
Raji MlXmSpVv[3Srb36gRZN{[Xl? NXnINGppOC53wrFOwG0> MUC3NkBp MkK2ZYJwdGm|aHXzJIF2fG:yaHHnfeKh NVHubJRUOjV2NE[zO|c>
SK-MEL-28  M1[3PWZ2dmO2aX;uJGF{e2G7 NWHyO2hvOzBibl2= NGP4Onk3KGh? MVTpcoR2[2W|IFey5qCUVSClZXzsMYN6[2ynIHHydoV{fA>? NH61[GEzPTNzM{CxNC=>
H157 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFOy[3NKSzVyPUGuNFMhyrFiMD6wOEBucXV{TR?= NHH0fZozPTJ3N{mxNS=>
Jurkat M3vQ[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3rPWVEuOyCwTR?= MWm0POKhcA>? MoLmSG1UVw>? NUTrfm5y\GWlcnXhd4V{KH[rYXLs[UBk\WyuIH71cYJmenNiZH;z[UBl\XCnbnTlcpRtgQ>? M2rjXlI2OTV4MUS2
CEM MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NInWdmYyNTNibl2= MVy0POKhcA>? MkDQSG1UVw>? Monn[IVkemWjc3XzJJZq[WKuZTDj[YxtKG63bXLldpMh\G:|ZTDk[ZBmdmSnboTsfS=> NWrQT5lLOjVzNU[xOFY>
P12 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXjWc|JlOS1|IH7N NGS0[2Y1QMLiaB?= NFPDNlhFVVOR M1HmfIRm[3KnYYPld{B3cWGkbHWgZ4VtdCCwdX3i[ZJ{KGSxc3Wg[IVx\W6mZX70cJk> MWCyOVE2PjF2Nh?=
KB NIPibolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH3PZ|FKSzVyPUCuNFA1QSEEsTCwMlAxODFizszN NEfKPW4zPTB3OEWyOi=>
KBv200 (ABCB1) MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmPWTWM2OD1yLkO0OlIhyrFiMD6wNFY3KM7:TR?= M13zWFI2ODV6NUK2
SUDHL6  M{jMSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1G4T|HjiIoQvF2= NFuzXFI1QC95MjDo M4fX[olvcGmkaYTzJINmdGxidnnhZoltcXS7IIPp[45q\mmlYX70cJk> NXPqPVlVOjR7NkG2NFQ>
SUDHL6  MVLGeY5kfGmxbjDBd5NigQ>? MoPYNgKBkc7:TR?= MWC3NkBp NVzlfopkcW6mdXPld{B{cWewaX\pZ4FvfCCjcH;weI91cWNibX;ydIhwdG:peTDjbIFv\2W|IHPveJJme3SnZDD3bZRpKEKFTEGxRUB{cVKQQR?= M{\OSFI1QTZzNkC0
HCT-116 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoS3S2k2OD13IH7N NWXveZlROjR7Mke4OVc>
SKNBe2C MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV3JR|UxRTN{LklCtVQvOCCwTR?= NVjFOo9MOjR7MkG5NlA>
IGNR91 NXzrb4RPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4PGN2lEPTB;MkSuN:KyOS55IH7N NYDxUpB{OjR7MkG5NlA>
SKNAS NG\ZR2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1vuNWlEPTB;MT61xtExNjJibl2= NUPxVWlzOjR7MkG5NlA>
LAN1 NHT6cIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV;lWZdtUUN3ME2yMlPDuTBwMjDuUS=> NVm0NGJyOjR7MkG5NlA>
SHSY5Y MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4HJVWlEPTB;OD6yxtExNjZibl2= NFi1bFUzPDl{MUmyNC=>
A549-WT MmfxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWLJR|UxRTF7LkSzO{DDuSByLkW5OEAhdk1? NVPTenVmOjR6NUi4Nlc>
A549-R NUXMU2J3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWrOZXZIUUN3ME2xNk4yPzhiwsGgNE4{OzNiIH7N MY[yOFg2QDh{Nx?=
MCF-7-WT MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX3xdo92UUN3ME2xO{44PTJiwsGgNE4zOThiIH7N MX6yOFg2QDh{Nx?=
MCF-7-R MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXjJR|UxRTVwNUO5JOKyKDBwMUS0JEBvVQ>? MmHiNlQ5PTh6Mke=
A549-R NHLLUVVEgXSxdH;4bYNqfHliQYPzZZk> MX7JR|UxRTF{LkG3PEDDuSByLkOzN{BvVQ>? MX2yOFg2QDh{Nx?=
MCF-7-R NEO2fXVEgXSxdH;4bYNqfHliQYPzZZk> NE\2foVKSzVyPUWuOVM6KMLzIECuNVQ1KG6P NUPWVmY3OjR6NUi4Nlc>
SW620 M1Hybmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUTJR|UxRTdwOECgxtEhOC5yODDuUS=> M3HQTlI1PzJ4N{O5
SW620/AD300 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFryXJpKSzVyPUmwPU43OCEEsTC4MlkyKG6P NIfZWmozPDd{NkezPS=>
HEK293/pcDNA3.1 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV7JR|UxRTFwNEWgxtEhOC5{MDDuUS=> MVKyOFczPjd|OR?=
HEK293/ABCC1 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXexO4RKUUN3ME2xPU4zQSEEsTCyMlA5KG6P M3rydlI1PzJ4N{O5
TCC M2XiVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF;3eWYzPCCq NGfzWoFKSzVyPUewJI5O NYH6XnZnOjR5MU[5OFQ>
TCC MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlfMOFghcA>? M4\wPWlEPTB;NUCgcm0> MnLCNlQ4OTZ7NES=
HepG2/ADM NGnWbYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUHJR|UxRTJwN{i2N:KyOC5{M{exJO69VQ>? Mk\LNlQ4ODR3NU[=
HepG2 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnfWTWM2OD1yLkCxNVXDuTBwMECxO{DPxE1? MmqzNlQ4ODR3NU[=
MCF-7/ADR MkO4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGLxSmpKSzVyPUSuOFgzPsLzMD6yNFcxKM7:TR?= MlvKNlQ4ODR3NU[=
MCF-7 MnnZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NULM[W1ZUUN3ME2wMlAyPToEsUCuNFA3OiEQvF2= MWmyOFcxPDV3Nh?=
A-172  M13mR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYjOSGdyOC5zwrFOwG0> M1H5PVI1Nzd{IHi= MV\pcohq[mm2czDj[YxtKGe{b4f0bEB1cW2nIHTldIVv\GWwdHz5 Mo\vNlQ2OzB{M{W=
U-251MG MoLGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{HtUlAvOcLizszN NG\vVIEzPC95MjDo MUXpcohq[mm2czDj[YxtKGe{b4f0bEB1cW2nIHTldIVv\GWwdHz5 NETGcZYzPDV|MEKzOS=>
DLD-1 Moi0SpVv[3Srb36gRZN{[Xl? NEHvdI4yODBibl2= MoXrOFghcA>? MlO4dJJwdW:2ZYOgVnVPYDNiZHXt[ZRpgWyjdHnvcuKh M2qwNlI1PDB|NEWz
CCD18Co NWnsZllUTnWwY4Tpc44hSXO|YYm= M1\Vd|ExOCCwTR?= MlXhOFghcA>? NYS3SYxVeHKxbX;0[ZMhWlWQWEOg[IVu\XSqeXzheIlwdsLi MkOzNlQ1ODN2NUO=
DLD-1 NVjvdI9{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NULSOVUxOC1zMECwJI5O Ml7JOFghcA>? MnLobY5pcWKrdIOgZ4VtdCCpcn;3eIgh\G:|ZTDk[ZBmdmSnboTsfS=> NWTvbllEOjR2MEO0OVM>
CCD18Co MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXy0[2xyOC1zMECwJI5O NHXUNFI1QCCq MnT5bY5pcWKrdIOgZ4VtdCCpcn;3eIgh\G:|ZTDk[ZBmdmSnboTsfS=> M4LKc|I1PDB|NEWz
HepG2 NHvtb5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3H4NVI1KGh? M1radGlEPTB;NUKuOgKBkc7:TR?= M4TCTlI1OzRzNki4
HEK293/pcDNA3.1 NVuwUHRCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUTJR|UxRTBwMEC0xtExNjByMEOg{txO MViyOFI5PDd6Mx?=
HEK293/MRP1 NHq2cJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{K2emlEPTB;MD6wOVXDuTBwMEGyNEDPxE1? MoXnNlQzQDR5OEO=
Ramos M1rMUGFxd3C2b4Ppd{BCe3OjeR?= MnLsNwKBkc7:TR?= MUm0PEBp M4HRUYlv\HWlZYOgN|QvPiYEsUGuPVImKGGyb4D0c5Nqew>? MlXuNlQzPTZ2OUG=
NCI-H1299/pcDNA3 NHXhSYpE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NHm5e2MxNTJyIH7N M1HTOFk3KGh? M3XBNIlvcGmkaYTzJINmdGxidnnhZoltcXS7IHTvd4Uh\GWyZX7k[Y51dHl? MmSzNlQyPzdyMUK=
H1299/ICAM-3 NFLmXXpE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NG\6Z4QxNTJyIH7N MXy5OkBp MmnTbY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliZH;z[UBl\XCnbnTlcpRtgQ>? M{L2dlI1OTd5MEGy
NCI-H1299/pcDNA3 MXnGeY5kfGmxbjDBd5NigQ>? MmDpNU82NzFyL{KwxsBvVQ>? M{e1d|k3KGh? NIf2VVdqdmS3Y3XzJINt\WG4YXflJI9nKGOjc4Dhd4V{NTNuIEisJFktKGGwZDDQRXJR MUSyOFE4PzBzMh?=
H1299/ICAM-3 NIr3OYNHfW6ldHnvckBCe3OjeR?= NGfO[nQyNzVxMUCvNlDDqG6P NV;DTY46QTZiaB?= M3XpPYlv\HWlZYOgZ4xm[X[jZ3Wgc4Yh[2G|cHHz[ZMuOyxiODygPUwh[W6mIGDBVnA> NGT0UFYzPDF5N{CxNi=>
W1 M2DEZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{j6emlEPTB;MD6wNFMzKM7:TR?= M{fPflI1OTRyMUe2
W1VR NU\4RpViT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIXUNGxKSzVyPUCuNFU3KM7:TR?= M1PWNVI1OTRyMUe2
K562 MmD6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYTJR|UxRTBwMEOyJOKyKDBwMECxJEDPxE1? NVfLW2pNOjRzM{W5N|c>
K562/ADR MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXvJR|UxRTNwMk[xJOKyKDBwNEGyJO69VQ>? NELNe5EzPDF|NUmzOy=>
K562 NX7PTnVpSXCxcITvd4l{KEG|c3H5 MWOwMlMh|ryP MVOyOEBp M4DFOYlv\HWlZYOgZZBweHSxc3nzJJNq\26rZnnjZY51dHl? MnG0NlQyOzV7M{e=
K562/ADR MXHBdI9xfG:|aYOgRZN{[Xl? M3LOSVMh|ryP MXqyOEBp M4LyU4lv\HWlZYOgZZBweHSxc3nz NH34WnMzPDF|NUmzOy=>
A549 NYXiT4M5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV\MfZg2UUN3ME2wMlExKMLzIECuNFMh|ryP MmTzNlM6PzFyN{W=
K562 Ml7UR4VtdCCYaXHibYxqfHliQYPzZZk> MVizMlc26oDVNkFCpI5O M1TwV|czyqCqwrC= NWrpT2o1cW6qaXLpeJMh[2WubDD2bYFjcWyrdImg[I9{\SCmZYDlcoRmdnSueR?= MViyN|g4PzJ{Mx?=
lucena M135cmNmdGxiVnnhZoltcXS7IFHzd4F6 MlniN{44PeLCk{[wxsBvVQ>? MmXaO|LDqGkEoB?= NU[xWZVrdm9iZX\m[YN1 M1H1dFI{QDd5MkKz
FEPS M4HodWNmdGxiVnnhZoltcXS7IFHzd4F6 MkP2N{44PeLCk{[wxsBvVQ>? MmToO|LDqGkEoB?= Mn30co8h\W[oZXP0 NXzkd3RkOjN6N{eyNlM>
A2780 MonmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYPVSFRiUUN3ME2zMlUhdU1? MnHYNlM5Ojl{MEO=
ACHN NXjMbJF7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmTZTWM2ODxyLkGgcW0> M2LOT|I{QDJ7MkCz
U-937 NUL1PJpNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1vXTmlEPTB:M{Sgcm0> MmjNNlM5Ojl{MEO=
Jurkat M2jwcWFxd3C2b4Ppd{BCe3OjeR?= MlrZOeKh|rypL33sxsA> MV[yOEBp NYHWbZlXcW6mdXPld{BieG:ydH;zbZMhe2mpbnnmbYNidnSueR?= NXnGXIFzOjN6MUC0NFk>
Jurkat MnvwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFK4ZZY2yqEQvHevcYzDqA>? M{\Nc|I1KGh? MkPXZZJz\XO2IFr1dotifCClZXzsd{BqdiCJMj;NJJBp[XOn NW\UW44xOjN6MUC0NFk>
Hep-2 M4q3cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXzJR|UxRTBwMEVCtVAvODFizszN NHLL[o4zOzd6MESyOC=>
Hep-2/v M17uVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml23TWM2OD1zLklCtVAvOjBizszN M33NeVI{PzhyNEK0
SGC-7901 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlfkNE0yOCEQvHevcYw> NH;hUXozPC92OD:3NkBp MYnpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCmb4PlJIFv\CC2aX3lJIRmeGWwZHXueEBu[W6wZYK= NXvoe4l{OjN5NEO1O|I>
SGC-7901/VCR M3yyNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHf3dIQxNTFyIN88[{9udA>? NHm1RoEzPC92OD:3NkBp MUjpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCmb4PlJIFv\CC2aX3lJIRmeGWwZHXueEBu[W6wZYK= MXqyN|c1OzV5Mh?=
SGC-7901 MoP1RZBweHSxc3nzJGF{e2G7 MlTCbY5lfWOnczDhdI9xfG:|aYOgd4lodmmoaXPhcpRtgQ>? MkeyNlM4PDN3N{K=
SGC-7901/VCR NUPaRlZpSXCxcITvd4l{KEG|c3H5 MWnpcoR2[2W|IHHwc5B1d3OrczDzbYdvcW[rY3HueIx6 NIHhbmYzOzd2M{W3Ni=>
KB-3-1 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF3jO2tKSzVyPUGuOlYhyrFiMD6xOlIh|ryP MnrTNlM3PzN2NEW=
KB-C2 NGXxXWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWjJR|UxRTJyMj61OkDDuSB2Mj60PFEh|ryP NYHyVVFzOjN4N{O0OFU>
KB-3-1 NXzCOY5KT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFfPToFKSzVyPUGuNlYhyrFiMD6wNlch|ryP MWeyN|Y4OzR2NR?=
KB-V1 NIL5WmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEHnfVlKSzVyPUKwPE45PSEEsTCyNE41KM7:TR?= MXqyN|Y4OzR2NR?=
HEK293/pcDNA3.1 NFuwPJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYj2c2VbUUN3ME2yOE4yKMLzIECuNlA1KM7:TR?= Ml;qNlM3PzN2NEW=
HEK293/ABCB1 M2\SXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1\K[GlEPTB;M{WxNk45KMLzIEO3PE4{QTFizszN Mom5NlM3PzN2NEW=
A549/EGFP  M12zZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoTiNE4xOS1zMECwJO69VQ>? MXfJR|UxRTh4LkegxtEhOjlwMTFOwG0> MVOyN|Y{PDJ6Mh?=
A549/Slug NIrqZpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH3VOWMxNjBzLUGwNFAh|ryP NGHaS4VKSzVyPUmuO{DDuSB|LkGg{txO NWDPXI9kOjN4M{SyPFI>
JFCR39  MmnDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkXqNUDDvU1? NG\TNVczPCCq MUnEUXNQ MXTtZZJs\WSueTDpcoNz\WG|ZYOgeIhmKG63bXLldkBw\iCJMj;NJJBp[XOnIHPlcIx{ MV2yN|U6QDJ5Nh?=
A549 NWTGXJlzTnWwY4Tpc44hSXO|YYm= MVGxNFAhdk1? MorCNVYhcA>? M1ficmROW09? NEnje5Rt\WGmczD0c{BiKGyxc4Ogc4YhdWmlcn;0eYJ2dGW| M2LEe|I{PTl6Mke2
SGC7901 MlzpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXPJR|UxRTFwMkdihKnDueLCiUCuNVEh|rypL33s NV\o[ld6OjN3NkS0PFI>
SGC7901/LV-NC MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXLI[VQyUUN3ME2xMlc46oDLwsJihKkxNjF4IN88[{9udA>? NGjvXXAzOzV4NES4Ni=>
SGC7901/LV-SGO1 MnLDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUfYNlZvUUN3ME20MlM36oDLwsJihKkxNjN5IN88[{9udA>? MUSyN|U3PDR6Mh?=
SGC7901/VCR MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGrydWlKSzV|PUKwMlU{6oDLwsJihKkyNjl4IN88[{9udA>? NEXNUWgzOzV4NES4Ni=>
SGC7901/VCR-NC NGf6PXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGjYUZFKSzVyPUG5Mlg36oDLwsJihKkzNjBzIN88[{9udA>? MXuyN|U3PDR6Mh?=
SGC7901/VCR-si-SGO1 MoPRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnKyTWM2OD14LkG45qCKyrIkgJmxMlA{KM7:Zz;tcC=> NVnxXGFLOjN3NkS0PFI>
SGC7901/ADR MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NITydWNKSzVyPUeuPFXjiIoEsfMAjVAvPjRizsznM41t MXqyN|U3PDR6Mh?=
SGC7901/ADR-NC NFnVW2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3jZ[2lEPTB;OD65N-KBkcLz4pEJNE43QCEQvHevcYw> NXztVIhZOjN3NkS0PFI>
SGC7901/ADR-si-SGO1 M3TwTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{j6bWlEPTB;Mz60OwKBkcLz4pEJNE4zQSEQvHevcYw> NY[1WHNQOjN3NkS0PFI>
SH-SY5Y  NEfxRZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYjLSZByOC5yMEGtNVAh|ryP MoHqNlQhcA>? NUi2U5NrUUN3ME2wMlEyO8LzMD6wNVIh|ryP Mn7mNlMyOjlyNkW=
SH-SY5Y  NEW2VYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXSwMlAxOS1zMDFOwG0> M3PhNlQ5KGh? MlXiTWM2OD1yLkC3POKyOC5yMEmg{txO NWDjeHY1OjNzMkmwOlU>
SH-SY5Y  Mn:yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3u5bVAvODBzLUGwJO69VQ>? NEjFb|A4OiCq NYD4NYt3UUN3ME2wMlA2OcLzMD6wNFgh|ryP M3vVcVI{OTJ7ME[1
SH-SY5Y MlXURZBweHSxc3nzJGF{e2G7 NIHiVFcxNjFizszN MWiwMVI1KGh? NH3kOlRqdmS3Y3XzJIFxd3C2b4Ppd{Bw\iCVSD3TXVV[KGOnbHzzJIZwdGyxd3nu[{Bk\WyuIHP5Z4xmKGG{cnXzeEBifCC2aHWgS|IwVSCyaHHz[S=> M2\FSFI{OTJ7ME[1
SH-SY5Y M3XDRmFxd3C2b4Ppd{BCe3OjeR?= MX6wMlEh|ryP MUKwMVI1KGh? MWTpcoR2[2W|IH3peI91cWNiYYLy[ZN1yqB? NFv2PGIzOzF{OUC2OS=>

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
MPM2 / Cyclin B1 / Cdc25c / p-Cdc2 / Cdc2 / Aurora B / p-H3 / p-PLK1; 

PubMed: 26156322     


MOLT-4 Cells were treated with vincristine (0.3, 1, and 3 nM) alone or co-treated with SAHA (500 nM) for 24 h. Then, total cell lysates were obtained to evaluate the G2/M phase regulatory protein expression and the tubulin acetylation. Data are expressed as mean values ± SD of at least three separate determinations. S SAHA, V vincristine

26156322
Growth inhibition assay
Cell viability ; 

PubMed: 26156322     


MOLT-4 cells were treated with various concentrations of vincristine for 24 and 48 h, respectively.  Cell viability was measured by MTT assay.

26156322
In vivo Vincristine (3 mg/kg) administrated by a single i.p. injection to mice bearing bilateral subcutaneous xenografts Rh12 or Rh18, induces mean growth delay of >120 and >52 day, and repopulating fractions of 0.06% and 5%, respectively. [6] Vincristine acts on subcutaneous colon 38 tumors in mice by host cell-mediated vascular effects as well as by direct tubulin-mediated cytotoxicity. Vincristine (5 mg/kg) reduces tumor blood flow of tumors by nearly 75% . [7]

Protocol

Cell Research:[1]
+ Expand
  • Cell lines: B16 melanoma cell
  • Concentrations: 10 nM
  • Incubation Time: 3 days
  • Method: Cells are plated in 2 mL of medium in 35-mm plates at a concentration of about 5 × 104 cells/mL and grow for 24 h at 37 ℃ in an atmosphere of 5% CO2 and 95% air. Then medium is replaced with fresh medium lacking or containing 4 nM drug and proliferation is continued for 3 days. Cell counts are done each day in a Coulter Counter after detaching the cells with trypsin and EDTA.
    (Only for Reference)
Animal Research:[6]
+ Expand
  • Animal Models: Human rhabdomyosarcoma xenografts Rh12
  • Formulation: Water solutioin
  • Dosages: 3 mg/kg
  • Administration: A single i.p. administration
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL (108.33 mM)
Water 60 mg/mL (65.0 mM)
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
Saline
For best results, use promptly after mixing.
30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 923.04
Formula

C46H58N4O14S

CAS No. 2068-78-2
Storage powder
in solvent
Synonyms Leurocristine

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT03981510 Recruiting Diagnostic Test: 3D-Transit Constipation|Childhood Acute Lymphoblastic Leukemia|Neurofibromatosis 1|Chronic Constipation With Overflow University of Aarhus June 2019 Not Applicable

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    I want to use the product #S1421 for mouse in vivo, could you please give us your advice about administration method?

  • Answer:

    According to the reference cited on our website, we test the solubility of S1421 Staurosporine in 4% DMSO/saline, and it is a suspension at 5 mg/mL. The compound can also be dissolved in the vehicle 4% DMSO/30% PEG 300/10% Tween 80/saline at 5 mg/ml as a clear solution for injection.

Microtubule Associated Signaling Pathway Map

Related Microtubule Associated Products

Tags: buy Vincristine sulfate | Vincristine sulfate supplier | purchase Vincristine sulfate | Vincristine sulfate cost | Vincristine sulfate manufacturer | order Vincristine sulfate | Vincristine sulfate distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID